Mugdha V. Joglekar, Wilson K. M. Wong, Pooja S. Kunte, Hrishikesh P. Hardikar, Reshmi A. Kulkarni, Ikhlak Ahmed, Ryan J. Farr, Nhan Ho Trong Pham, Madilyn Coles, Simranjeet Kaur, Cody L. Maynard, Riley Hayward, Vinod Thorat, Aniruddha Pant, Ammira A. Akil, Kim C. Donaghue, Alicia J. Jenkins, Milan K. Piya, Maria E. Craig, William M. Hague, Chittaranjan S. Yajnik, Juliana C. N. Chan, A. M. James Shapiro, Elizabeth A. Davis, Timothy W. Jones, Stephen E. Gitelman, Ronald C. W. Ma, Flemming Pociot, Anandwardhan A. Hardikar
{"title":"基于微rna的1型糖尿病动态风险评分","authors":"Mugdha V. Joglekar, Wilson K. M. Wong, Pooja S. Kunte, Hrishikesh P. Hardikar, Reshmi A. Kulkarni, Ikhlak Ahmed, Ryan J. Farr, Nhan Ho Trong Pham, Madilyn Coles, Simranjeet Kaur, Cody L. Maynard, Riley Hayward, Vinod Thorat, Aniruddha Pant, Ammira A. Akil, Kim C. Donaghue, Alicia J. Jenkins, Milan K. Piya, Maria E. Craig, William M. Hague, Chittaranjan S. Yajnik, Juliana C. N. Chan, A. M. James Shapiro, Elizabeth A. Davis, Timothy W. Jones, Stephen E. Gitelman, Ronald C. W. Ma, Flemming Pociot, Anandwardhan A. Hardikar","doi":"10.1038/s41591-025-03730-7","DOIUrl":null,"url":null,"abstract":"<p>Identifying individuals at high risk of type 1 diabetes (T1D) is crucial as disease-delaying medications are available. Here we report a microRNA (miRNA)-based dynamic (responsive to the environment) risk score developed using multicenter, multiethnic and multicountry (‘multicontext’) cohorts for T1D risk stratification. Discovery (wet and dry lab) analysis identified 50 miRNAs associated with functional β cell loss, which is a hallmark of T1D. These miRNAs measured across <i>n</i> = 2,204 individuals from four contexts (4C: Australia, Denmark, Hong Kong SAR People’s Republic of China, India) led to a four-context, miRNA-based dynamic risk score (DRS) that effectively stratified individuals with and without T1D. Generative artificial intelligence was used to create an enhanced four-context, miRNA-based DRS, which offered good predictive power (area under the curve = 0.84) for T1D stratification in a separate multicontext validation dataset (<i>n</i> = 662), and accurately predicted future exogenous insulin requirement at 1 hour of islet transplantation. In a clinical trial assessing the imatinib drug therapy, baseline miRNA signature, rather than clinical characteristics, distinguished drug responders from nonresponders at 1 year. This study harnessed machine learning/generative artificial intelligence approaches, identifying and validating a miRNA-based DRS for T1D discrimination and treatment efficacy prediction.</p>","PeriodicalId":19037,"journal":{"name":"Nature Medicine","volume":"9 1","pages":""},"PeriodicalIF":58.7000,"publicationDate":"2025-06-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"A microRNA-based dynamic risk score for type 1 diabetes\",\"authors\":\"Mugdha V. Joglekar, Wilson K. M. Wong, Pooja S. Kunte, Hrishikesh P. Hardikar, Reshmi A. Kulkarni, Ikhlak Ahmed, Ryan J. Farr, Nhan Ho Trong Pham, Madilyn Coles, Simranjeet Kaur, Cody L. Maynard, Riley Hayward, Vinod Thorat, Aniruddha Pant, Ammira A. Akil, Kim C. Donaghue, Alicia J. Jenkins, Milan K. Piya, Maria E. Craig, William M. Hague, Chittaranjan S. Yajnik, Juliana C. N. Chan, A. M. James Shapiro, Elizabeth A. Davis, Timothy W. Jones, Stephen E. Gitelman, Ronald C. W. Ma, Flemming Pociot, Anandwardhan A. Hardikar\",\"doi\":\"10.1038/s41591-025-03730-7\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p>Identifying individuals at high risk of type 1 diabetes (T1D) is crucial as disease-delaying medications are available. Here we report a microRNA (miRNA)-based dynamic (responsive to the environment) risk score developed using multicenter, multiethnic and multicountry (‘multicontext’) cohorts for T1D risk stratification. Discovery (wet and dry lab) analysis identified 50 miRNAs associated with functional β cell loss, which is a hallmark of T1D. These miRNAs measured across <i>n</i> = 2,204 individuals from four contexts (4C: Australia, Denmark, Hong Kong SAR People’s Republic of China, India) led to a four-context, miRNA-based dynamic risk score (DRS) that effectively stratified individuals with and without T1D. Generative artificial intelligence was used to create an enhanced four-context, miRNA-based DRS, which offered good predictive power (area under the curve = 0.84) for T1D stratification in a separate multicontext validation dataset (<i>n</i> = 662), and accurately predicted future exogenous insulin requirement at 1 hour of islet transplantation. In a clinical trial assessing the imatinib drug therapy, baseline miRNA signature, rather than clinical characteristics, distinguished drug responders from nonresponders at 1 year. This study harnessed machine learning/generative artificial intelligence approaches, identifying and validating a miRNA-based DRS for T1D discrimination and treatment efficacy prediction.</p>\",\"PeriodicalId\":19037,\"journal\":{\"name\":\"Nature Medicine\",\"volume\":\"9 1\",\"pages\":\"\"},\"PeriodicalIF\":58.7000,\"publicationDate\":\"2025-06-05\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Nature Medicine\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1038/s41591-025-03730-7\",\"RegionNum\":1,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"BIOCHEMISTRY & MOLECULAR BIOLOGY\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Nature Medicine","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1038/s41591-025-03730-7","RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOCHEMISTRY & MOLECULAR BIOLOGY","Score":null,"Total":0}
A microRNA-based dynamic risk score for type 1 diabetes
Identifying individuals at high risk of type 1 diabetes (T1D) is crucial as disease-delaying medications are available. Here we report a microRNA (miRNA)-based dynamic (responsive to the environment) risk score developed using multicenter, multiethnic and multicountry (‘multicontext’) cohorts for T1D risk stratification. Discovery (wet and dry lab) analysis identified 50 miRNAs associated with functional β cell loss, which is a hallmark of T1D. These miRNAs measured across n = 2,204 individuals from four contexts (4C: Australia, Denmark, Hong Kong SAR People’s Republic of China, India) led to a four-context, miRNA-based dynamic risk score (DRS) that effectively stratified individuals with and without T1D. Generative artificial intelligence was used to create an enhanced four-context, miRNA-based DRS, which offered good predictive power (area under the curve = 0.84) for T1D stratification in a separate multicontext validation dataset (n = 662), and accurately predicted future exogenous insulin requirement at 1 hour of islet transplantation. In a clinical trial assessing the imatinib drug therapy, baseline miRNA signature, rather than clinical characteristics, distinguished drug responders from nonresponders at 1 year. This study harnessed machine learning/generative artificial intelligence approaches, identifying and validating a miRNA-based DRS for T1D discrimination and treatment efficacy prediction.
期刊介绍:
Nature Medicine is a monthly journal publishing original peer-reviewed research in all areas of medicine. The publication focuses on originality, timeliness, interdisciplinary interest, and the impact on improving human health. In addition to research articles, Nature Medicine also publishes commissioned content such as News, Reviews, and Perspectives. This content aims to provide context for the latest advances in translational and clinical research, reaching a wide audience of M.D. and Ph.D. readers. All editorial decisions for the journal are made by a team of full-time professional editors.
Nature Medicine consider all types of clinical research, including:
-Case-reports and small case series
-Clinical trials, whether phase 1, 2, 3 or 4
-Observational studies
-Meta-analyses
-Biomarker studies
-Public and global health studies
Nature Medicine is also committed to facilitating communication between translational and clinical researchers. As such, we consider “hybrid” studies with preclinical and translational findings reported alongside data from clinical studies.